Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Eylea
Biotech
Unity's stock tumbles after eye treatment fails to match Eylea
Unity’s eye treatment failed to match Eylea at 20 weeks—the only time stamp in which the candidate was inferior to Regeneron’s blockbuster.
Gabrielle Masson
Mar 24, 2025 11:11am
Opthea's eye disease drug defeated by Eylea in phase 3
Mar 24, 2025 5:24am
Regeneron snaps up eye biotech, snaring science but not staff
Jan 2, 2025 3:58pm
Innovent's anti-VEGF drug matches Eylea in eye disease trial
Mar 19, 2024 10:36am
Unity preps for Eylea battle following extended midstage test
Apr 24, 2023 10:25am
Kodiak asset matches Regeneron's Eylea in macular edema phase 3
Aug 8, 2022 9:53am
